Lord David Prior Appointed as Chair of e-therapeutics' Board of Directors

e-therapeutics plc, a UK-based company leveraging computational power and biological data to develop RNAi medicines, has announced the appointment of Lord David Prior as the new Chair of its Board of Directors. He will replace Professor Trevor Jones, who will remain a non-executive director.

Lord Prior has a significant background in healthcare. He chaired Norfolk and Norwich University Hospitals NHS Trust and the Care Quality Commission before serving as Parliamentary Under Secretary of State for Health. His roles also included positions at the Department of Business, Energy & Industrial Strategy, University College London Hospitals, NHS England, and Genomics England.

Lord Prior holds a law degree from Cambridge University and has finance experience from Lehman Brothers and Lazard Freres. He has been involved in various senior positions, including at British Steel. He is currently Deputy Chairman UK and Global Senior Advisor at Lazard and holds multiple chairmanships, including at Protas and the Cambridge Life Sciences Council.

Ali Mortazavi, CEO of e-therapeutics, expressed enthusiasm for Lord Prior's appointment, citing his extensive healthcare experience that will aid the company's progression, particularly in their GalOmic™ programs for RNAi therapies.